Precision Medicine Quarterly

Roche Expands Molecular Business With Digital PCR, Lower-Volume Cobas Instruments

2022-03-24T18:04:22-05:00March 24th, 2022|

With two new instrument launches planned in the US this year, Roche is continuing to broaden its molecular diagnostic offerings. One key move Roche is making this year is a foray into the digital PCR market with its Digital LightCycler. Still "a very new technology" to laboratories, digital PCR allows for absolute nucleic acid [...]

FDA Approves Novartis Radiologand Pluvicto for PSMA-Positive mCRPC With Imaging CDx

2022-03-24T18:00:37-05:00March 24th, 2022|

NEW YORK – The US Food and Drug Administration on Wednesday approved Novartis' targeted radioligand therapy Pluvicto (177Lu-PSMA-617 or lutetium Lu 177 vipivotide tetraxetan) for progressive, metastatic castration-resistant prostate cancer (mCRPC) patients whose tumors express the prostate-specific membrane antigen (PSMA). The agency also approved Novartis' gallium-68-labeled imaging product Locametz (gallium Ga 68 gozetotide) as [...]

LifeMine Therapeutics Nets $175M in Series C, Inks GSK Deal to Advance Genomically Informed Drugs

2022-03-24T17:57:13-05:00March 24th, 2022|

LifeMine Therapeutics on Wednesday announced that it has inked a partnership with GlaxoSmithKline and raised $175 million in a Series C financing, which it will put toward genomically informed drug discovery and development efforts, including in precision oncology. Through the strategic R&D partnership, GSK will tap into LifeMine's Avatar-Rx drug discovery platform to identify [...]

Researchers ID Gut Microbiome Impact on CAR T-Cell Therapy Outcomes

2022-03-24T17:52:39-05:00March 24th, 2022|

Patients with certain blood cancers may respond differently to autologous CAR T-cell therapy depending on the makeup of their gut microbiome and whether they've received antibiotics in the weeks leading up to treatment, recent research suggests. In a study published Monday in Nature Medicine, researchers from Memorial Sloan Kettering and the University of Pennsylvania [...]

Australian Government Invests A$28.1M to Establish Genomics Agency

2022-03-24T17:48:26-05:00March 24th, 2022|

The Australian government said this week that it has invested A$28.1 million (US$21.1 million) to establish Genomics Australia, a new agency tasked with supporting the integration of genomic medicine into Australia's healthcare system. According to a statement issued by the office of Greg Hunt, Minister for Health and Aged Care, a taskforce in the [...]

Real-World Impact of Pharmacogenomics and Comprehensive Medication Management Revealed in New Coriell Life Sciences Case Study

2022-03-18T09:42:13-05:00March 18th, 2022|

Answering the call for real-world data on the clinical and economic outcomes of pharmacogenomics (PGx) and comprehensive medication management (CMM), Coriell Life Sciences (CLS) – an international leader in precision medicine – has released new research on the impact of these tools at scale. These findings are detailed in a new peer-reviewed study entitled [...]

Labcorp Enters Into Strategic Relationship with Prisma Health

2022-03-18T09:37:36-05:00March 18th, 2022|

Labcorp (NYSE: LH), a leading global life sciences company, is entering into a strategic laboratory relationship with Prisma Health, a nonprofit and the largest health system in South Carolina. Through this new relationship, Labcorp will acquire select assets of Prisma Health’s outreach laboratory business. In addition, Labcorp and Prisma Health have entered into a [...]

New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis

2022-03-18T09:34:39-05:00March 18th, 2022|

Novartis has announced that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab). This data was compiled from the ongoing, open-label, long-term extension phase 3b ALITHIOS study and from post-marketing reports submitted through the Novartis Global Safety Database. [...]

Genomic Data Release Opens New Paths for Discovery

2022-03-18T09:30:41-05:00March 18th, 2022|

The All of Us Research Program reached an important milestone this week with the release of its initial genomic dataset. Nearly 100,000 whole genome sequences (WGS) and 165,000 genotyping arrays are now available within the Researcher Workbench, less than two years after the beta launch of the platform. Nearly 50% of the data come [...]

NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

2022-03-12T13:09:58-05:00March 12th, 2022|

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th. Dr. Kulkarni most recently served [...]

Go to Top